Patent application number | Description | Published |
20080227829 | Neurogenic compounds - The invention relates to method(s) of use of the compound(s) described herein, e.g. method for stimulating neurogenesis, including in vitro neurogenesis, by contacting neuronal progenitor cells with an effective amount of the compound(s) described herein; method for treatment of a subject in need of treatment with a neurogenic compound; and/or for treatment of a disease or condition associated with damage to the hippocampus. The subject may be a human or a veterinary animal. | 09-18-2008 |
20100184152 | TARGET-ORIENTED WHOLE GENOME AMPLIFICATION OF NUCLEIC ACIDS - Disclosed herein are methods of amplifying target nucleic acid sequences (e.g., DNA or RNA), particularly from a very small amount of starting material, such as a single cell. These methods involve targeting the amplification of specific sequence(s) by use of sequence-specific primers and random primers for whole genome amplification using multiple displacement amplification. Generally, the provided methods are referred to herein as “target-oriented” whole genome amplification. Starting material for target-oriented whole genome amplification can be any sample containing DNA or RNA, however, the technique is particularly suitable for very small amounts of starting material, such as a few cells, a single cell, or a single nucleus. The methods provide amplified nucleic acid (including the target sequence of interest) that can subsequently be analyzed. | 07-22-2010 |
20100235310 | Temporally dynamic artificial neural networks - An apparatus, article and method containing an artificial neural network that, after training, produces new trainable nodes such that input data representative of a first event and input data representative of a second event both activate a subset of the new trainable nodes. The artificial neural network can generate an output that is influenced by the input data of both events. In various embodiments, the new trainable nodes are sequentially produced and show decreasing trainability over time such that, at a particular point in time, newer produced nodes are more trainable than earlier produced nodes. The artificial neural network can be included in various embodiments of methods, apparatus and articles for use in predicting or profiling events. | 09-16-2010 |
20110045996 | ROBUST REGRESSION BASED EXON ARRAY PROTOCOL SYSTEM AND APPLICATIONS - An analysis technique for genetic data to detect alternative spliced exons. Exon expression of similar data is analyzed using a robust regression technique to find outliers to the main regression. False outliers are detected and removed. The remaining outliers are identified as potential alternative splicing events. | 02-24-2011 |
20110172105 | GREPSEQ: An Almost Inexhaustible, Cost-Effective, High-Throughput Protocol for the Generation of Selector Sequences - Provided are compositions, libraries, and methods for the synthesis of transcripts that can be processed to produce nucleic acid capture probes. Also provided methods for using such nucleic acid capture probes in a variety of downstream applications, including, e.g., determining the sequence of an exon-exon junction. | 07-14-2011 |
20120003655 | IDENTIFICATION OF NEUROPROTECTIVE AGENTS USING PRO-INFLAMMATORY HUMAN GLIAL CELLS - Provided herein are methods for, inter alia, identifying new therapeutic agents using human cell-based models. | 01-05-2012 |
20120107286 | PLURIPOTENT STEM CELLS - Methods and compositions for the generation and use of footprint-free human induced pluripotent stem cells are provided. | 05-03-2012 |
20120129835 | SCHIZOPHRENIA METHODS AND COMPOSITIONS - Methods of preparing and using neural cells derived from human induced pluripotent stem cell (hiPSCs), particularly hiPSCs derived from subjects with schizophrenia are provided. The hiPSC-derived neural cells can be used to screen test compounds and to identify schizophrenia marker functions. The hiPSC-derived neural cells can be used to diagnose and/or assess the severity of schizophrenia in a subject. Further, may the hiPSC-derived neural cells from a subject be used as an in vitro system to identify the most effective candidate among existing drugs for that specific subject (i.e. personalized medicine). | 05-24-2012 |
20130004985 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS - Provided herein are methods and compositions useful in treating neurological disorders. | 01-03-2013 |
20130315886 | RETROELEMENTS AND MENTAL DISORDERS AND METHODS OF MEASURING L1 RETROTRANSPOSITION - A method of treating increased non-LTR retrotransposition in a cell. The method includes exposing a neural cell to a retrotransposition inhibitor in an amount sufficient to decrease the non-LTR retrotransposition in the neural cell or a progeny of the neural cell. In various embodiments, the non-LTR retrotransposition involves at least one L1 retrotransposon. Also provided is a method of assaying retrotransposition in neural cells. The method includes sorting synchronized neural cells of the same genetic background into single neural cells, and subjecting one or more of the sorted single neural cells to quantitative polymerase chain reaction amplification of at least one retrotransposon. In addition, a method of identifying an inhibitor of retrotransposition and a identifying a neural condition associated with non-LTR retrotransposition are provided. | 11-28-2013 |
20140038896 | Retroelements and mental disorders and methods of measuring L1 retrotransposition - A method of treating increased non-LTR retrotransposition in a cell. The method includes exposing a neural cell to a retrotransposition inhibitor in an amount sufficient to decrease the non-LTR retrotransposition in the neural cell or a progeny of the neural cell. In various embodiments, the non-LTR retrotransposition involves at least one L1 retrotransposon. Also provided is a method of assaying retrotransposition in neural cells. The method includes sorting synchronized neural cells of the same genetic background into single neural cells, and subjecting one or more of the sorted single neural cells to quantitative polymerase chain reaction amplification of at least one retrotransposon. In addition, a method of identifying an inhibitor of retrotransposition and a identifying a neural condition associated with non-LTR retrotransposition are provided. | 02-06-2014 |